Physician profile
John H Stein
NPI 1265980452
$3,266.90
in general payments reported to CMS, 2019-2025
18 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.35 · 2022: $676 · 2023: $869 · 2024: $582 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Education: $14.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.47 |
| Education | $14.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,057.89 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $343.80 | 2022-2025 | Rexulti, Nuedexta |
| Indivior INC. | $308.23 | 2023-2025 | Sublocade |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.70 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $231.86 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $161.54 | 2023-2025 | Auvelity |
| Alkermes, INC. | $148.34 | 2022-2023 | Vivitrol |
| Neurocrine Biosciences, INC. | $148.10 | 2022-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $142.11 | 2022-2024 | Trintellix |
| Lundbeck LLC | $127.70 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $87.89 | 2023-2025 | Spravato |
| Braeburn INC. | $71.32 | 2024 | Brixadi |
| Teva Pharmaceuticals USA, INC. | $69.75 | 2023-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $48.75 | 2022 | |
| Almatica Pharma LLC | $28.76 | 2023-2025 | Loreev Xr, Sertraline Hcl |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $25.26 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $14.25 | 2023 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $13.65 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.